ACAT2 and nonpapillary renal cell carcinoma: Studies have shown that ACAT2 may suppress the progression of clear cell renal cell carcinoma (ccRCC) by promoting apoptosis of tumour cells and inhibiting epithelial-mesenchymal transition (EMT) [39, 40].